GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹21 Cr | ₹16 Cr | ₹22 Cr | ₹13 Cr | ₹75 Cr |
What is the latest Contingent Liabilities ratio of GLAND PHARMA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹21 Cr |
| Mar2024 | ₹16 Cr |
| Mar2023 | ₹22 Cr |
| Mar2022 | ₹13 Cr |
| Mar2021 | ₹75 Cr |
How is Contingent Liabilities of GLAND PHARMA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹21 Cr | 37.24 | |
| Mar2024 | ₹16 Cr | -29.41 | |
| Mar2023 | ₹22 Cr | 72.94 | |
| Mar2022 | ₹13 Cr | -82.91 | |
| Mar2021 | ₹75 Cr | - | |
Compare Contingent Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹27,298.3 Cr | -0.8% | -12.1% | 2.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,000.0 Cr | 1.5% | 6.9% | 13.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,076.0 Cr | -0.8% | 1.7% | 14% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹148,510.0 Cr | 3.2% | 9% | 44.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,921.0 Cr | 1.1% | 5% | 16.4% | Stock Analytics | |
| CIPLA | ₹106,150.0 Cr | 0.3% | -1.3% | -9% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | -0.8% |
-12.1% |
2.2% |
| SENSEX | -5% |
-9.6% |
3.1% |
You may also like the below Video Courses